In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90 values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by ≤8 μg/ml of ceftolozane-tazobactam.
Departments of Medicine and Clinical Microbiology, Health Sciences Centre.
A
A
Walkty
J A
JA
Karlowsky
H
H
Adam
M
M
Baxter
P
P
Lagacé-Wiens
D J
DJ
Hoban
G G
GG
Zhanel
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002170:Canada; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects; D006761:Hospitals; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D012189:Retrospective Studies; D000078142:Tazobactam
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; C519491:ceftolozane; D010397:Penicillanic Acid; D002442:Ceftazidime; D000078142:Tazobactam